EP 99: ESC 23 Review: Interventional Trials with Dr Mirvat Alasnag

Published: Sept. 4, 2023, 1:32 p.m.

In this week's Parallax, Dr Ankur Kalra's guest is Dr Mirvat Alasnag. Dr Alasnag is an interventional cardiologist at King Fahad Armed Forces Hospital (KFAFH) in Saudi Arabia. Additionally, she serves as the Editor-in-Chief at Current Cardiovascular Imaging Reports and is a member of the Board of Trustees at SCAI.\nDr Alasnag and Dr Kalra provide a comprehensive review of the key highlights from ESC Congress 2023. Dr Alasnag distills the background and latest evidence from key interventional trials, emphasizing their significance for patient care.\nTune in to discover the strategies that Dr Kalra and Dr Alasnag are currently employing and gain insights into how these data will shape their future decision-making in the catheterization laboratory. Don't miss this informative discussion at the forefront of interventional cardiology.\n \nTrials included:\nFIRE: Physiology-Guided Complete PCI in Older MI Patients\nMULTISTARS AMI: MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction\nILUMIEN IV: Optical coherence tomography-guided coronary stent implantation compared to angiography\nOCTOBER: European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction\nOCT Vs IVUS Vs Angiography Guidance\nOCTIVUS: Optical coherence tomography non-inferior to intravascular ultrasound for stent guidance\n \nWhat are the take-home messages from ESC 2023 for interventional cardiologists? How can we interpret the results for patient care? What new data have the power to change guidelines?\n\nQuestions and comments can be sent to \u201cpodcast@radcliffe-group.com\u201d and may be answered by Ankur in the next episode.\nGuests: @mirvatalasnag Host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.